Induction Chemotherapy Followed by Radiotherapy in Patients with Cervical Lymph Node Metastases from Unknown Primary Carcinoma

被引：2
作者：
Seol Y.M. [1 ]
Choi Y.J. [1 ]
Lee B.J. [2 ]
Wang S.G. [2 ]
机构：
[1] Division of Hematology/Oncology, Department of Internal Medicine, Pusan National University Hospital, Medical Research Institute, Busan
[2] Department of Otolaryngology, Pusan National University Hospital, Medical Research Institute, Busan
来源：
Indian Journal of Otolaryngology and Head & Neck Surgery | 2015年 / 67卷 / Suppl 1期
关键词：
Head and neck cancer; Induction chemotherapy; Lymph node metastasis; Unknown primary;
D O I：
10.1007/s12070-014-0773-8
中图分类号：
学科分类号：
摘要：
Cervical metastases from unknown primary tumors are rare and no clear therapeutic options are available. This study was performed to assess the efficacy and safety profiles of induction chemotherapy followed radiotherapy in patients with cervical lymph node metastases from unknown primary cancer. Patients with histological diagnosis of cervical lymph-node metastasis from carcinoma with an unknown primary cancer underwent induction chemotherapy followed by radiotherapy. All patients had squamous cell carcinoma. Induction chemotherapy consisted of 3–4 cycles every 3 weeks of docetaxel (day 1.70 mg/m2) and cisplatin (day 1.75 mg/m2). Radiation therapy (RT) was started with in 10 weeks of the last cycle of chemotherapy, and it was administered 5 days per week. It was given in daily fractions of (1.8) Grays (Gy) of 2 Gy and the total dose to the primary tumor was 70–74 Gy. Neck dissection was reserved for residual disease after definitive radiotherapy. Overall survival, recurrent free survival, and locoregional control were calculated using the Kaplan–Meier method. Twenty one patients with an unknown primary cancer underwent induction chemotherapy and radiotherapy. After induction chemotherapy, 6 patients achieved CR and 8 patients achieved PR. The overall response rate after radiation, was 90.4 % (19 of 21 patients). Neutropenia and infection were the most common grade 3–4 adverse event during induction chemotherapy. Mucositis and dermatitis were the most common grade 3–4 toxicities during radiotherapy. With a median follow-up of 50.6 months, the estimated 2 years OS rates were 71 ± 6 %, respectively. The median OS was 42 months (95 % confidence interval CI 8–65 months). The recurrent-free survival rate at 2 years was 57 %, respectively. In the patients with responder to induction chemotherapy, superior relapse free survival and overall survival rate observed. No occurrence of primary cancer was observed during the follow-up period. Induction chemotherapy followed RT for unknown primarycancer has provided good overall and disease-free survival in all the patients with anacceptable rate of complications. The use of induction chemotherapy and radiationtherapy for more advanced disease led to good clinical results with reasonable toxicities. © 2014, Association of Otolaryngologists of India.
引用
收藏
页码：74 / 78
页数：4
相关论文
共 21 条
  • [11] Denis F., Garaud P., Bardet E., Et al., Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma, J Clin Oncol, 22, pp. 69-76, (2004)
  • [12] Brizel D.M., Albers M.E., Fisher S.R., Et al., Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer, N Engl J Med, 338, pp. 1798-1804, (1998)
  • [13] Wendt T.G., Grabenbauer G.G., Rodel C.M., Et al., Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study, J Clin Oncol, 16, pp. 1318-1324, (1998)
  • [14] Haddad R.I., Shin D.M., Recent advances in head and neck cancer, N Engl J Med, 359, pp. 1143-1154, (2008)
  • [15] Brockstein B., Haraf D.J., Rademaker A.W., Et al., Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience, Ann Oncol, 15, pp. 1179-1186, (2004)
  • [16] Nieder C., Ang K.K., Cervical lymph node metastases from occult squamous cell carcinoma, Curr Treat Options Oncol, 3, pp. 33-40, (2002)
  • [17] Harper C.S., Mendenhall W.M., Parsons J.T., Et al., Cancer in neck nodes with unknown primary site: role of mucosal radiotherapy, Head Neck, 12, pp. 463-469, (1990)
  • [18] Haigentz M., Cohen E.E., Wolf G.T., Et al., The future of induction chemotherapy for head and neck squamous cell carcinoma, Oral Oncol, 48, pp. 1065-1067, (2012)
  • [19] Strojan P., Haigentz M., Bradford C.R., Et al., Chemoradiotherapy versus total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma, Oral Oncol, 49, pp. 283-286, (2012)
  • [20] Hafkamp H.C., Manni J.J., Haesevoets A., Et al., Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas, Int J Cancer, 122, pp. 2656-2664, (2008)
123